Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cristofanilli

Showing results (191-200 of 439) with videos related to

Pageof 44
Sort By:
International Journal of Molecular Sciences|October 6, 2016
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast CancerZhaomei Mu, Naoual Benali-Furet, Georges Uzan, et al.
Oncotarget|December 17, 2017
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?Young Kwang Chae, Ayush Arya, Lauren Chiec, et al.
Annals of Surgery|January 23, 2024
Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic CancerDhavan Shah, Amy Wells, Madison Cox, et al.
Journal of Biomolecular Screening|July 20, 2010
Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotypeFredika M Robertson, Marcia A Ogasawara, Zaiming Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapyFrancisco J Esteva, Aysegul A Sahin, Massimo Cristofanilli, et al.
Breast Cancer Research : BCR|March 14, 2020
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studiesJohannes Ettl, Seock-Ah Im, Jungsil Ro, et al.
Cancer Causes & Control : CCC|November 1, 2014
Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variablesChun Wang, Jesse Civan, Yinzhi Lai, et al.
Breast Cancer Research : BCR|March 25, 2021
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practiceAngela DeMichele, Massimo Cristofanilli, Adam Brufsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 24, 2009
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary dataSelin Carkaci, Homer A Macapinlac, Massimo Cristofanilli, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingJulia R Trosman, Christine B Weldon, William J Gradishar, et al.
Pageof 44

Showing results (191-200 of 439) with videos related to

Sort By:
Pageof 44
International Journal of Molecular Sciences|October 6, 2016
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast CancerZhaomei Mu, Naoual Benali-Furet, Georges Uzan, et al.
Oncotarget|December 17, 2017
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?Young Kwang Chae, Ayush Arya, Lauren Chiec, et al.
Annals of Surgery|January 23, 2024
Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic CancerDhavan Shah, Amy Wells, Madison Cox, et al.
Journal of Biomolecular Screening|July 20, 2010
Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotypeFredika M Robertson, Marcia A Ogasawara, Zaiming Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapyFrancisco J Esteva, Aysegul A Sahin, Massimo Cristofanilli, et al.
Breast Cancer Research : BCR|March 14, 2020
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studiesJohannes Ettl, Seock-Ah Im, Jungsil Ro, et al.
Cancer Causes & Control : CCC|November 1, 2014
Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variablesChun Wang, Jesse Civan, Yinzhi Lai, et al.
Breast Cancer Research : BCR|March 25, 2021
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practiceAngela DeMichele, Massimo Cristofanilli, Adam Brufsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 24, 2009
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary dataSelin Carkaci, Homer A Macapinlac, Massimo Cristofanilli, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingJulia R Trosman, Christine B Weldon, William J Gradishar, et al.
Pageof 44